Antiretroviral Activity and Safety of Abacavir in Combination with Selected HIV-1 Protease Inhibitors in Therapy-Naive HIV-1-Infected Adults

Gulick R.M. , Mellors J. W. , Havlir D. , Eron J.J. , Gonzalez C. , McMahon D. , Richman D.D. , Valentine F.T. , Jonas L. , Meibohm A. , Emini E.A. , & Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy. New England Journal of Medicine 1997; 337: 734–739.

Hammer S. , Squires K. , Hughes M. , Grimes J.M. , Demeter L.M. , Currier J.S. , Eron J.J. Jr. , Feinberg J.E. , Balfour H.H. Jr. , Deyton L.R. , Chodakewitz J.A. , & Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337: 725–733.

Gulick R.M. , Mellors J. W. , Havlir D. , Eron J.J. , Gonzalez C. , McMahon D. , Jonas L. , Meibohm A. , Holder D. , Schleif W.A. , Condra J.H. , Emini E.A. , Isaacs R. , Chodakewitz J.A. , & Richman D.D. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. Journal of the American Medical Association 1998; 280: 35–41.

Palella F.J. Jr. , Delaney K.M. , Moorman A.C. , Loveless M.O. , Fuhrer J. , Satten G.A. , Aschman D.J. , & Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338: 853–860.

Ledergerber B. , Egger M. , Opravil M. , Telenti A. , Hirschel B. , Battegay M. , Vernazza P. , Sudre P. , Flepp M. , Furrer H. , Francioli P. , & Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863–868.

Saag M.S. , Sonnerborg A. , Torres R.A. , Lancaster D. , Gazzard B.G. , Schooley R.T. , Romero C. , Kelleher D. , Spreen W. , & LaFon S. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. AIDS 1998; 12: F203–F209.

Staszewski S. , Katlama C. , Harrer T. , Massip P. , Yeni P. , Cutrell A. , Tortell S.M. , Harrigan R.P. , Steel H. , Lanier R.E. , & Pearce G. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998; 12: F197–F202.

Fischl M. , Greenberg S. , Clumeck N. , Peters B. , Rubio R. , Gould J. , Boone G. , West M. , Spreen B. , & Lafon S. Ziagen. (Abacavir, ABC, 1592) combined with 3TC/ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral therapy naive subjects (CNA3003). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 1999; Abstract. 19.

Staszewski S. , Keiser P. , Gathe J. , Haas D. , Montaner J. , Johnson M. , Delfraissy J. F. , Cutrell A. , Lafon S. , Thorborn D. , Pearce G. , Spreen W. , & Tortell S. Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA, 1999; Abstract 505.

Tisdale M. , Alnadaf T. , & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41: 1094–1098.

Lanier R. , Danehower S. , Daluge S. , Cutrell A. , Tisdale M. , Pearce G. , Spreen B. , Lafon S. , Kemp S.D. , Bloor S. , & Larder B.A. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). Antiviral Therapy 1998; 3(Suppl 1):36.

Lanier E.R. , Stone C. , Griffin P. , Thomas D. , & Lafon S. Phenotypic sensitivity to 1592 (abacavir) in the presence of multiple genotypic mutations: correlation with viral load response. 12th World AIDS Conference, Geneva, Switzerland, June 1998; Abstract 686.

Miller V. , Ait-Khaled M. , Stone C. , Griffin P. , Mesogiti D. , Cutrell A. , Harrigan R. , Staszewski S. , Katlama C. , Pearce G. , & Tisdale M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14: 163–171.

Harrigan P.R. , Stone C. , Griffin P. , Najera I. , Bloor S. , Kemp S. , Tisdale M. , & Larder B. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. Journal of Infectious Disease 2000; 181: 912–920.

Ross L. , Johnson M. , Graham N. , Shaefer M. , & St Clair M. The RT 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. Journal of Human Virology 1999; 2: 290–295.

Squires K.E. , Gulick R. , Tebas P. , Santana J. , Mulanovich V. , Clark R. , Yangco B. , Marlowe S.I. , Wright D. , Cohen C. , Cooley T. , Mauney J. , Uffelman K. , Schoellkopf N. , Grosso R. , & Stevens M. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy. AIDS 2000; 14: 1591–1600.

Murphy R.L. , Katlama C. , Johnson V. , Squires K. , Horban A. , Gatell J.M. , Clotet B. , Staszewski S. , Van Leeuwen R. , Clumeck N. , Moroni M. , Pavia A.T. , Schmidt R.E. , Gonzalez-Lahoz J. , Antunes F. , Gulick R. , Banhegyi D. , Montaner J.S.G. , Sommadossi J. P. , Lange J. The Atlantic study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA, 1999; Abstract LB–22.

Carr A. , Emery S. , Kelleher A. , Law M. , & Cooper D.A. CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1996; 13: 320–326.

Autran B. , Carcelain G. , Li T.S. , Blanc C. , Mathez D. , Tubiana R. , Katlama C. , Debre P. , & Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112–116.

Lederman M.M. , Connick E. , Landay A. , Kuritzkes D.R. , Spritzler J. , St Clair M. , Kotzin B.L. , Fox L. , Chiozzi M.H. , Leonard J.M. , Rousseau F. , Wade M. , Roe J.D. , Martinez A. , & Kessler H. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. Journal of Infectious Disease 1998; 178: 70–79.

Pakker N.G. , Notermans D.W. , de Boer R.J. , Roos M.T. , de Wolf F. , Hill A. , Leonard J.M. , Danner S.A. , Miedema F. , & Schellekens P.T. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Medicine 1998; 4: 208–214.

Al-Haarthi , Siegel J. , Spritzler J. , Pottage J. , Agnoli M. , & Landay A. Maximum suppression of HIV replication leads to the restoration of HIV specific responses in early HIV disease. AIDS 2000; 14: 761–770.

Stuart J.C. , Boucher C.A. , Roos M. , Miedema F. , Borleffs J.C. , & Hamann D. Highly active antiretroviral therapy (HAART) increases circulating naive CD8+ T cell counts. 12th World AIDS Conference, Geneva, Switzerland, 1998; Abstract 22345.

Kaul D.R. , Cinti S.K. , Carver P.L. , & Kazanjian P.H. HIV protease inhibitors: advances in therappy and adverse reactions, including metabolic complications. Pharmacotherapy 1999; 19: 281–298.

Takuda T.N. , Struble K.A. , & Piscitelli S.C. Protease inhibitors for the treatment of human immunodeficiency virus infection. American Journal of Health-System Pharmacology 1998; 55: 233–254.

Hetherington S. , Steel H. , Naderer O. , Cutrell A. , Powell W. , & Sykes R. Hypersensitivity reactions during therapy with abacavir: analysis of 636 cases for clinical presentation and risk factors. 7th Conference on Retroviruses and Opportunistic infections, San Francisco, Calif., USA, 2000; Abstract 60.

Vigouroux C. , Gharakhanian S. , Salhi Y. , Nguyen T.H. , Adda N. , Rozenbaum W. , & Capeau J. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metabolism 1999; 25: 383–392.

Tsiodras S. , Mantzoros C. , Hammer S. , & Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Pharmacotherapy 2000; 20: 727–734.

Hartmann M. , & Petzoldt D. Lipodystrophy syndrome in HIV infection. Archives of Internal Medicine 2000; 160: 2050–2056.

Sullivan A.K. , & Nelson M.R. Marked hyperlipidemia on ritonavir therapy. AIDS 1997; 11: 938–939.

Carpenter C.J.C. , Cooper D.A. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Hammer S.M. , Hirsch M.S. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S. , Richman D.D. , Saag M.S. , Schechter M. , Schooley R.T. , Thompson M.A. , Vella S. , Yeni P.G. , & Volberding P.A. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society–USA Panel. Journal of the American Medical Association 2000; 283: 383–391.